AJ201
Beyond's analysis on AJ201
- — AnnJi Pharmaceutical moves its SBMA drug AJ201 into a pivotal Phase 3 trial, positioning the firm to capture the first approved disease‑modifying therapy for a rare neurodegenerative condition
- — AnnJi Pharmaceutical advances AJ201 into pivotal Phase 3 trial for spinal and bulbar muscular atrophy, positioning a potential first‑in‑class therapy for a rare disease
Recent news mentioning AJ201
- — AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)
- — AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)